TRUFACIAL™ Skin Rejuvenation Device Captures 2024 People’s Choice Award at Octane’s Prestigious Aesthetics Tech Forum

2 years ago

Award-Winning Presentation on Trufacial Groundbreaking Skin Technology Redefines the Standard for At-Home Skin Health and BeautyPHILADELPHIA--(BUSINESS WIRE)--#httpstwittercomtrufacial--TRUFACIAL™, a breakthrough professional-grade,…

TRUFACIAL™ Skin Rejuvenation Device Captures 2024 People’s Choice Award at Octane’s Prestigious Aesthetics Tech Forum

2 years ago

Award-Winning Presentation on Trufacial Groundbreaking Skin Technology Redefines the Standard for At-Home Skin Health and BeautyPHILADELPHIA--(BUSINESS WIRE)--#httpstwittercomtrufacial--TRUFACIAL™, a breakthrough professional-grade,…

Retreat Behavioral Health Offers Free Virtual Workshops to Families and Friends of Patients

2 years ago

Substance Abuse and Mental Health Recovery Innovator Retreat Behavioral Health Extends Healing and Support Resources to Patient Family MembersPALM SPRINGS,…

Dermata to Present at the Emerging Growth Conference on February 7, 2024

2 years ago

- Company to provide a corporate overview followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE…

CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira’s Products

2 years ago

Correction: Extended clarification.HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide…

Voom Medical Devices Welcomes Dr. Joël Vernois as Advisor and Editor-in-Chief of Journal of Minimally Invasive Bunion Surgery (JMIBS)

2 years ago

NEW YORK--(BUSINESS WIRE)--#bunionplasty--Voom™ Medical Devices, Inc. ("Voom"), a visionary medical device company focused on new paradigms in minimally invasive bunion…

Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22

2 years ago

LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023…

New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval

2 years ago

Fibromyalgia candidate TNX-102 SL hits primary endpoint of daily pain reduction (p=0.00005)Combination of broad-spectrum relief and favorable tolerability seen as…

Corporate Update on Clinical Evaluation of MedMira’s Products

2 years ago

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update…

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

2 years ago

CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live…